Antares Pharma Inc., of Ewing, N.J., has licensed to Pfizer Inc.'s Consumer Healthcare Business Unit one of its drug delivery technologies to develop an undisclosed product on an exclusive basis for North America. New York-based Pfizer will assume full cost and responsibility for all clinical development, manufacturing and commercialization of the product in the licensed territory, which also includes certain nonexclusive territories outside of North America. Antares will receive undisclosed up-front payments, development milestones and sales-based milestones, as well as royalties on net sales for three years post-launch in the U.S.